Cytokinetics Incorporated has announced the issuance of stock options and restricted stock units (RSUs) to 46 new employees who joined the company in July and August 2025. The company has granted options to purchase a total of 105,169 shares of common stock and 70,879 RSUs. The RSUs will vest over a three-year period, with 40% vesting on the first and second anniversaries of the grant date and the remaining 20% on the third anniversary. The stock options are priced at $38.67 per share, reflecting the closing price on August 15, 2025, and will vest over four years, with an initial 25% vesting after one year, followed by monthly vesting for the remaining shares. These stock options have a 10-year term.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.